Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients

American Journal of Nephrology

Volumn 27, Issue 6, 2007, Pages 639-642

  Cozzolino, Mario ^a,b   Biondi, Maria Luisa ^a   Galassi, Andrea ^a   Gallieni, Maurizio ^a   Melzi D'Eril, Gian Vico ^a   Brancaccio, Diego ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

Author keywords

Fetuin A; Genetic polymorphism; Haemodialysis; Vascular calcification

Indexed keywords

ALPHA2 HEREMANS SCHMID GLYCOPROTEIN; FETUIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLOBIN GENE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; BLOOD PROTEINS; CALCINOSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; ITALY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS;

EID: 35548941449     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108360     Document Type: Article

References (16)

1. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906.
2. Longenecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 2002;13:1918-1927.
3. London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;14:S305-S309.
4. Guérin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
5. Blacher J, Guérin AP, Pannier B, et al: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-2439.
6. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436.
7. 2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. J Biol Chem 1996;271:20789-20796.
8. 2 Heremans-Schmid glycoprotein/fetuin A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-366.
9. Ketteler M, Bongartz P, Westenfeld R, et al: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003;361:827-833.
10. Cozzolino M, Galassi A, Biondi ML, et al: Serum fetuin-A levels link inflammation and cardiovascular calcification in haemodialysis patients. Am J Nephrol 2006;26:423-429.
11. Stenvinkel P, Wang K, Qureshi AR, et al: Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392.
12. 2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 2007;92:345-352.
13. 2-Heremans-Schmid glycoprotein polymorphism with late-onset Alzheimer's disease in Italians. Neurosci Lett 2005;386:176-178.
14. Russo D, Corrao S, Mirando I, et al: Progression of coronary artery calcification in predialysis patients. Am J Nephrol 2007;27:152-158.
15. Mazzaferro S, Pasquali M, Pugliese F, et al: Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis. Am J Nephrol 2007;27:75-83.
16. Cozzolino M, Dusso AS, Slatopolsky E: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001;12:2511-2516.